Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Alector Inc (Alector) The company offers a portfolio of therapeutic candidates designed to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Its pipeline products include AL101, which treats Alzheimer’s Disease; AL137-ABC, for Alzheimer’s Disease; AL050-ABC, which targets Parkinson’s Disease, Gaucher Disease, and Lewy Body Dementia; ADP064-ABC, for Alzheimer’s Disease and Frontotemporal Dementia; ADP062-ABC, which targets Parkinson’s Disease; and ADP065-ABC, which treats Neurodegenerative Diseases. The company also develops the proprietary Alector Brain Carrier blood-brain barrier platform to enhance the delivery and penetration of therapeutics into the brain. Alector is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
131 Oyster Point Blvd., Suite 600, South San Francisco, California, 94080
Website
alector.com
Telephone
1 415 2315660
No of Employees
156
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALEC (NASD)
Revenue (2025)
$21.0M
-79.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-20.1%
(2025 vs 2024)
Market Cap*
$233.2M
Net Profit Margin (2025)
XYZ
-473.7%
(2025 vs 2024)
* As of and is in US$
Alector Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| AL101: Alzheimer’s Disease |
| AL137-ABC: Alzheimer’s Disease |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Alector Inc | Roche Holding AG | Eli Lilly and Co | Merck & Co Inc | Biogen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | South San Francisco | Basel | Indianapolis | Rahway | Cambridge |
| State/Province | California | Basel-Stadt | Indiana | New Jersey | Massachusetts |
| No. of Employees | 156 | 112,774 | 47,000 | 73,000 | 7,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Louis J. Lavigne | Chairman | Executive Board | 2023 | 76 |
| Arnon Rosenthal, Ph.D. | Chief Executive Officer; Director | Executive Board | 2013 | 70 |
| Neil Berkley | Chief Business Officer; Chief Financial Officer | Senior Management | 2025 | - |
| Clare Hunt | Chief People Officer | Senior Management | - | - |
| Giacomo Salvadore, M.D. | Chief Medical Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer